From dual inhibition to precision selectivity: the molecular rationale and clinical evolution of next-generation PARP1-selective inhibitors in solid tumors
{{output}}
Poly (ADP-ribose) polymerase inhibitors (PARPi) have revolutionized Homologous recombination deficient (HRD) solid tumors by using the synthetic lethality which BRCA 1/2 mutated cancer cells depend on for DNA repair. Standard PARP inhibitors such as olaparib, ... ...
